Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. ACAD | 0.00 |
Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:
ACAD) with a Equal-Weight and raises the price target from $27 to $28.